NOXXON Pharma is a clinical-stage biopharmaceutical company, which focuses on the development of proprietary therapeutics for the treatment of cancer. The Company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia.
Market capitalization (22-Oct-2020)
Closing stock price (22-Oct-2020)
NOXXON Pharma has 442 Twitter Followers. The number of followers has increased 4.3% month over month and increased 9% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was NOXXON Pharma founded?
NOXXON Pharma was founded in 1998.
Who are NOXXON Pharma key executives?
NOXXON Pharma's key executives are Aram Mangasarian and Jarl Ulf Jungnelius.
How many employees does NOXXON Pharma have?
NOXXON Pharma has 11 employees.
Who are NOXXON Pharma competitors?
Competitors of NOXXON Pharma include Mentrik Biotech, Telix Pharmaceuticals and ASLAN Pharmaceuticals.
Where is NOXXON Pharma headquarters?
NOXXON Pharma headquarters is located at 8 Max-Dohrn-Straße, Berlin.
Where are NOXXON Pharma offices?
NOXXON Pharma has an office in Berlin.
How many offices does NOXXON Pharma have?
NOXXON Pharma has 1 office.
Receive alerts for 300+ data fields across thousands of companies